Novel Immuno-epigenetic Based Platform for Patients With Peripheral T-cell Lymphoma (PTCL) and Cutaneous T-cell Lymphoma (CTCL): an International Phase Ib Study of Pembrolizumab Combined With Decitabine and Pralatrexate
Phase of Trial: Phase I
Latest Information Update: 23 Nov 2018
At a glance
- Drugs Decitabine (Primary) ; Pembrolizumab (Primary) ; Pralatrexate (Primary)
- Indications Cutaneous T-cell lymphoma; Peripheral T-cell lymphoma
- Focus Adverse reactions
- 13 Nov 2018 Planned End Date changed from 10 Dec 2020 to 1 Dec 2020.
- 13 Nov 2018 Planned primary completion date changed from 10 Sep 2019 to 1 Dec 2019.
- 13 Nov 2018 Status changed from not yet recruiting to recruiting.